Results 271 to 280 of about 305,001 (288)
Some of the next articles are maybe not open access.

Immunotherapy for acute myeloid leukemia

Current Oncology Reports, 2005
Immunotherapeutic strategies have become part of standard cancer treatment. Chimeric and humanized antibodies have demonstrated activity against a variety of tumors. Although the humanized anti-CD33 antibody HuM195 has only modest activity against overt acute myeloid leukemia (AML), it can eliminate minimal residual disease in acute promyelocytic ...
openaire   +2 more sources

Treatment of Acute Myeloid Leukemia

2010
The acute myeloid leukemias (AML) represent a heterogeneous group of malignancies derived from the pluripotent hematopoietic stem cell. These leukemias are generally characterized by genetic lesions that result in a combination of defects causing unregulated proliferation of cells and defects in cellular maturation (Gilliland and Griffin 2002).
Gibson, B   +3 more
openaire   +3 more sources

Pathophysiology of Acute Myeloid Leukemia

Acta Haematologica
<b><i>Background:</i></b> Acute myeloid leukemia (AML) is a biologically heterogenous disease arising in clonally proliferating hematopoietic stem cells. Sequential acquisition of mutations leads to expanded proliferation of clonal myeloid progenitors and failure of differentiation, leading to fulminant AML.
Franziska, Wachter, Yana, Pikman
openaire   +2 more sources

Immunophenotyping of Acute Myeloid Leukemia

2019
Immunophenotyping by multiparameter flow cytometry is a rapid and efficient technique to simultaneously assess and correlate multiple individual cell properties like size and internal complexity along with antigen expression in a population of cells. This method is utilized for rapid characterization of the blasts and classification of acute myeloid ...
Pallavi Kanwar, Galera   +2 more
openaire   +2 more sources

Angiogenesis in acute myeloid leukemia

Blood, 2000
We have read with interest the report of Padro et al[1][1] showing an increased angiogenesis in acute myeloid leukemia. Recently, other studies published in Blood also have shown that angiogenesis in acute myeloid leukemias is higher than in controls[2][2] and that it has an independent ...
DI RAIMONDO, FRANCESCO   +3 more
openaire   +3 more sources

Acute Myeloid Leukemia in the Elderly

Seminars in Oncology, 2008
The incidence of acute myeloid leukemia (AML) is increasing with age. As the results associated with standard intensive chemotherapy remain particularly disappointing in older patients, they represent an ideal target population for clinical and therapeutic investigations.
HervĂ©, Dombret   +2 more
openaire   +2 more sources

Childhood Acute Myeloid Leukemia

Current Treatment Options in Oncology, 2008
Despite the use of intensive chemotherapy and hematopoietic stem cell transplantation, approximately one-third of children with acute myeloid leukemia (AML) still suffer relapse of their disease. It is unlikely that improvements in outcome can be achieved by further intensification of conventional chemotherapy.
openaire   +2 more sources

Cytogenetics in acute myeloid leukemia

Current Oncology Reports, 2002
Cytogenetic analysis is the most important diagnostic tool for determining prognosis in acute myeloid leukemia (AML). In the majority of patients with AML, acquired clonal chromosome aberrations can be observed. Numerous recurrent karyotype abnormalities have been discovered in AML.
Claudia, Schoch, Torsten, Haferlach
openaire   +2 more sources

Adult Acute Myeloid Leukemia

Mayo Clinic Proceedings, 2006
Acute myeloid leukemia (AML) is a group of several different diseases, the treatment and outcome of which depend on several factors, including leukemia karyotype, patient age, and comorbid conditions. Despite advances in understanding the molecular biology of AML, its treatment remains challenging.
Elias J, Jabbour   +2 more
openaire   +2 more sources

Immunohistochemistry in Acute Myeloid Leukemia

2017
The World Health Organization's Classification of Tumours of Haematopoietic and Lymphoid Tissues (Swerdlow et al. (eds) WHO Classification of tumours of haematopoietic and lymphoid tissues, 4th edn. WHO Press, Lyon, 2008) created a classification scheme incorporating genetic, molecular, morphologic, and immunophenotypic characteristics.
openaire   +2 more sources

Home - About - Disclaimer - Privacy